Immutep (IMMP) EPS (Basic) (2011 - 2026)

Immutep's (IMMP) quarterly EPS (Basic) came in at -$0.4 in Q2 2026, down 176.4% quarter-over-quarter from -$0.14 in Q4 2024.

Analysis

Immutep (IMMP) EPS (Basic) (2011 - 2026) Analysis & Trends

Immutep (IMMP) has reported EPS (Basic) for 15 consecutive years, with -$0.4 the latest figure, recorded in Q2 2026.

For the quarter ending Q2 2026, EPS (Basic) changed N/A year-over-year to -$0.4; the trailing twelve-month figure through Jun 2026 stood at -$0.83 (changed N/A YoY), and the FY2026 full-year result was -$0.39, down 42.98% from the prior year.
EPS (Basic) retreated to -$0.4 in Q2 2026 per IMMP's latest filing, from -$0.14 in the prior quarter.
Across five years, EPS (Basic) topped out at -$0.14 in Q4 2024 and bottomed at -$0.4 in Q2 2026.
Historically, EPS (Basic) has averaged -$0.24 across 4 years, with a median of -$0.21 in 2023.
The sharpest annual moves came in 2022 and 2023: EPS (Basic) grew 26.04% in 2022, then retreated 1.7% in 2023.
Over 4 years, EPS (Basic) stood at -$0.17 in 2022, then declined by 1.7% to -$0.17 in 2023, then advanced by 14.75% to -$0.14 in 2024, then slumped by 176.4% to -$0.4 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered -$0.4, -$0.14, and -$0.26 for Q2 2026, Q4 2024, and Q2 2024 respectively.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Amgen	211.73 Bn	197.74 Bn	7.24 Bn	4.40
2	Gilead Sciences	180.92 Bn	177.74 Bn	6.22 Bn	-8.44
3	Vertex Pharmaceuticals	132.16 Bn	124.30 Bn	2.84 Bn	4.34
4	Regeneron Pharmaceuticals	82.89 Bn	74.90 Bn	3.93 Bn	12.62
5	Argenx Se	61.41 Bn	56.23 Bn	1.37 Bn	7.70
6	Moderna	53.99 Bn	48.85 Bn	52.00 Mn	-1.96
7	Alnylam Pharmaceuticals	34.48 Bn	31.18 Bn	992.69 Mn	1.23
8	Biogen	31.15 Bn	29.86 Bn	1.96 Bn	0.66
9	Roivant Sciences	30.05 Bn	30.05 Bn	1.16 Mn	-0.40
10	Immutep	51.68 Mn	51.68 Mn	-	-0.40

Historic Data

Download Data